Lorraine Registry of Multiple Sclerosis
RelSEP
1 other identifier
observational
6,000
1 country
1
Brief Summary
The RelSEP aims to register exhaustively every new case of multiple sclerosis (MS) occuring in Lorraine a French region, and follow up on them for an indefinite duration, registering disease evolution and intercurrent events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2003
CompletedFirst Submitted
Initial submission to the registry
August 19, 2016
CompletedFirst Posted
Study publicly available on registry
August 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
February 8, 2023
February 1, 2023
26.7 years
August 19, 2016
February 6, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
case occurence of multiple sclerosis
one year
Secondary Outcomes (1)
EDSS score
30 years
Interventions
Eligibility Criteria
Patients suffering from multiple sclerosis in Lorraine
You may qualify if:
- Having a confirmed multiple sclerosis diagnosis
- Living in Lorraine (French region)
You may not qualify if:
- Refusal to be registered
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CIC 1433 Épidémiologie clinique, Inserm, Université de Lorraine, CHRU de Nancy
Nancy, 54000, France
Related Publications (4)
Brissart H, Morele E, Baumann C, Perf ML, Leininger M, Taillemite L, Dillier C, Pittion S, Spitz E, Debouverie M. Cognitive impairment among different clinical courses of multiple sclerosis. Neurol Res. 2013 Oct;35(8):867-72. doi: 10.1179/1743132813Y.0000000232. Epub 2013 Jun 19.
PMID: 23816638BACKGROUNDBrissart H, Sauvee M, Latarche C, Dillier C, Debouverie M. Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis. Eur Neurol. 2010;64(6):345-50. doi: 10.1159/000322140. Epub 2010 Nov 13.
PMID: 21071951BACKGROUNDEl Adssi H, Debouverie M, Guillemin F; LORSEP Group. Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler. 2012 Sep;18(9):1244-50. doi: 10.1177/1352458512437811. Epub 2012 Feb 21.
PMID: 22354740RESULTBecker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol. 2015 May 13;15:79. doi: 10.1186/s12883-015-0330-4.
PMID: 25966681RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francis Guillemin, MD, PHD
CHRU Nancy
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Médecine coordonateur de module
Study Record Dates
First Submitted
August 19, 2016
First Posted
August 30, 2016
Study Start
May 1, 2003
Primary Completion (Estimated)
January 1, 2030
Study Completion (Estimated)
January 1, 2030
Last Updated
February 8, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will share
open to partnership